Echocardiographic dimensions and function in adults with primary growth hormone resistance (Laron syndrome)

Am J Cardiol. 2000 Jan 15;85(2):209-13. doi: 10.1016/s0002-9149(99)00642-6.

Abstract

Patients with primary growth hormone (GH) resistance-Laron Syndrome (LS)-have no GH signal transmission, and thus, no generation of circulating insulin-like growth factor-I (IGF-I), and should serve as a unique model to explore the controversies concerning the longterm effect of GH/IGF-I deficiency on cardiac dimension and function. We assessed 8 patients with LS (4 men, 4 women) with a mean (+/- SD) age of 38+/-7 years (range 22 to 45), and 8 aged-matched controls (4 men, 4 women) with a mean age of 38+/-9 years (range 18 to 47) by echocardiography at rest, following exercise, and during dobutamine administration. Left ventricular (LV) septum, posterior wall, and end-diastolic diameter were significantly reduced in untreated patients with LS compared with the control group (p<0.05 for all). Systolic Doppler-derived parameters, including LV stroke volume, stroke index, cardiac output, and cardiac index, were significantly lower (p<0.05 for all) than in the control subjects, whereas LV diastolic Doppler parameters, including mitral valve waves E, A, E/A ratio, and E deceleration time, were similar in both groups. LV ejection fraction at rest as well as the stress-induced increment of the LV ejection fraction were similar in both groups. Our results show that untreated patients with long-term IGF-I deficiency have reduced cardiac dimensions and output but normal LV ejection fraction at rest and LV contractile reserve following stress.

MeSH terms

  • Adult
  • Cardiotonic Agents
  • Dobutamine
  • Exercise Test
  • Female
  • Heart Defects, Congenital / diagnostic imaging*
  • Heart Defects, Congenital / physiopathology
  • Human Growth Hormone / deficiency
  • Human Growth Hormone / metabolism*
  • Humans
  • Male
  • Middle Aged
  • Syndrome
  • Ultrasonography
  • Ventricular Function, Left

Substances

  • Cardiotonic Agents
  • Human Growth Hormone
  • Dobutamine